The use of transarterial chemoembolization with radiotherapy led to improved survival outcomes for patients with unresectable hepatocellular carcinoma and portal vein tumor thrombus, compared with ...
Asymptomatic patients with portal vein thrombosis and patients with incomplete occlusions of the portal vein can remain untreated as long as they are followed up regularly (e.g. every 2-4 weeks). All ...
Update results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in hepatocellular carcinoma patients at high risk of recurrence after surgery—A single-arm, multicenter, phase II ...
Portal vein blood flow accounts for 75% of total hepatic blood flow, with the hepatic artery accounting for the remainder. As a result, portal vein occlusion may have significant consequences for ...
A randomized, multicenter controlled study was conducted from January 2016 to December 2017 in patients with resectable HCC and PVTT. Patients were randomly assigned to receive neoadjuvant RT followed ...
Please provide your email address to receive an email when new articles are posted on . Postprocedural imaging showed 10% of patients had new portal vein thrombosis after transarterial ...
Nurses and oncologists need to give portal vein thrombosis a closer look, according to one oncolgy nurse. Despite its deadly potential, portal vein thrombosis (PVT) is a frequently overlooked side ...
Background A 52-year-old man presented to hospital having experienced abdominal pain, abdominal distention and oliguria for 1 week. An abdominal CT scan revealed thrombosis in the superior mesenteric ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback